BENEVIR BIOPHARM
BeneVir's immunotherapies for cancer are designed to induce the immune system to rid the body of two types of tumor cells: those currently responsible for cancer and those responsible for tumor recurrence and poor clinical outcomes. This is a unique approach in the emerging field of cancer immunotherapy.
BENEVIR BIOPHARM
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2011-01-01
Address:
Gaithersburg, Maryland, United States
Country:
United States
Website Url:
http://www.benevirbiopharm.com
Total Employee:
1+
Status:
Active
Contact:
6465943703
Email Addresses:
[email protected]
Total Funding:
7 M USD
Technology used in webpage:
U.S. Server Location
Similar Organizations
Acublate
Acublate developing a HIFU device used to treat various types of solid tumors.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Cellestia
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Foghorn Therapeutics
Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,
HelioWave Technologies
HelioWave Technologies is leveraging innovative microfluidic-based systems to revolutionize the way of sterility of biopharma products.
InCytu
InCytu develops anticancer immunotherapies that use the patient's own immune system to selectively target and destroy tumor cells.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
Marcadia Biotech
Marcadia Biotech is focused on developing therapeutic products to improve the daily life of people with diabetes and obesity.
PhyNet Dermatology LLC
PhyNet's mission is to bring together high-quality, collaborative dermatology practices and empower
Current Employees Featured
Founder
Official Site Inspections
http://www.benevirbiopharm.com
- Host name: ecbiz193.inmotionhosting.com
- IP address: 198.46.81.213
- Location: El Segundo United States
- Latitude: 33.9214
- Longitude: -118.413
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90245
More informations about "BeneVir Biopharm"
Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy …
May 2, 2018 T-Stealth™ Oncolytic Virus Platform Expected to Further Strengthen Immunotherapy Platform and Capabilities HORSHAM, PA, May 2, 2018 – Janssen Biotech, …See details»
BENEVIR BIOPHARM, INC. | VentureRadar
DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and production in Denmark and …See details»
BeneVir Biopharm, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for BeneVir Biopharm, Inc. of Rockville, MD. Get the latest business insights from Dun & Bradstreet.See details»
BeneVir Biopharm, Inc. - LinkedIn
BeneVir Biopharm, Inc. | 480 followers on LinkedIn. ONCOLYTIC IMMUNOTHERAPY Immunotherapies are an exciting new class of therapies that utilize the immune system to …See details»
BeneVir Biopharm - Ownership and Business Overview - Mergr
BeneVir Biopharm, Inc. is a biopharmaceutical company specializing in the development of oncolytic immunotherapies. BeneVir Biopharm is based in Gaithersburg, Maryland. Company …See details»
Montgomery County, Maryland-based BeneVir Biopharm, Inc. to …
May 7, 2018 The Montgomery County Economic Development Corporation (MCEDC) is the lead public-private economic development organization for Montgomery County, Md. The …See details»
BeneVir Biopharm - Products, Competitors, Financials, Employees ...
About BeneVir Biopharm BeneVir is a privately held biopharmaceutical company founded in 2011 with offices and laboratories located in Rockville, MD. BeneVir is developing a novel platform …See details»
BeneVir Biopharm - Funding, Financials, Valuation & Investors
Maryland startup BeneVir is developing immunotherapy viruses that rid the body of two types of tumor cells.See details»
Nextsource | Company Profile | BeneVir Biopharm
Explore the company profile of BeneVir Biopharm (benevirbiopharm.com) featuring business details and insights, funding data, industry info, employee numbers, and more.See details»
BeneVir Biopharm - Crustdata Company Profile, Funding and Growth
About BeneVir Biopharm BeneVir's immunotherapies for cancer are designed to induce the immune system to rid the body of two types of tumor cells: those currently responsible for …See details»
BeneVir Biopharm - Crunchbase
Maryland startup BeneVir is developing immunotherapy viruses that rid the body of two types of tumor cells.See details»
Johnson & Johnson Acquire BeneVir Biopharm - Drug Discovery …
May 2, 2018 HC2 Holdings, a diversified holding company, announced today that BeneVir Biopharm, Inc., a privately-held biotechnology company developing oncolytic immunotherapies …See details»
BeneVir Biopharm, Inc. - Company Profile & Staff Directory
Search BeneVir Biopharm, Inc. Staff Directory Find accurate personal emails, work emails and phone numbers for employeesSee details»
Montgomery County, Maryland-Based Benevir Biopharm, Inc. To …
May 8, 2018 About MCEDC The Montgomery County Economic Development Corporation (MCEDC) is the official public-private organization representing Montgomery County, Md. The …See details»
Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy …
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the potential acquisition of BeneVir Biopharm, Inc. The …See details»
J&J could pay $1 billion for oncolytic virus firm BeneVir
May 4, 2018 Johnson & Johnson has bought oncolytic immunotherapy biotech BeneVir, adding immune-oncology drugs to a cancer pipeline dominated by antibodies and small molecules.See details»
Johnson & Johnson pens $140M deal for preclinical oncolytic virus ...
May 2, 2018 Johnson & Johnson is paying $140 million upfront to buy oncolytic immunotherapy startup BeneVir Biopharm. The outlay gives J&J control of preclinical prospects designed to …See details»
BENEVIR BIOPHARM, INC. - VentureRadar
Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and …See details»
J&J pays $140m upfront for cancer-busting virus firm BeneVir
May 3, 2018 Johnson & Johnson’s initial push into immuno-oncology is gathering pace with an agreement to acquire BeneVir Biopharm and a portfolio of oncolytic viruses designed to infect …See details»